

Subrata Ghosh and Andrzej S Tarnawski

Editors-in-Chief

World Journal of Gastroenterology

Dear Editors-in-Chief

Thank you very much for your e-mail. We are pleased to hear that our manuscript “A new prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy (NO: 69778)” will be accepted for publication if appropriately revised.

We are submitting the revised manuscript, on which we indicated where we made changes in response to the suggestions of reviewers in yellow highlights. We also indicated certain words or sentences in yellow highlights which were changed in consequence of the changes in response to the suggestions.

We thank you and the reviewers for providing insightful comments and useful suggestions that helped us to significantly improve our manuscript. We hope that you will now find our manuscript to be acceptable for publication and we look forward to your response.

Yours sincerely,

Yoon-Koo Kang, MD, PhD,

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine

88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea

Tel: +82-2-3010-3230; Fax: +82-2-3010-8772; E-mail: ykkang@amc.seoul.kr

[Reviewer Comments]

Reviewer #1

Reviewer #1:

Scientific Quality: Grade B (Very good)

Language Quality: Grade A (Priority publishing)

Conclusion: Minor revision

Specific Comments to Authors: The authors investigated prognostic factors for the advanced gastric cancer. I think this is a well written paper. Please provide limitations of this study.

→ We thank the reviewer for the comments. We added limitations of our study as your recommendation as follow:

Our study also has several limitations. First, despite a large number of patients, the generalizability of this study is limited by its single-center, retrospective design and the single ethnicity of its population. Second, our new prognostic model does not apply to patients who received treatment other than doublet chemotherapy, such as single, triplet, or doublet with trastuzumab. Third, this study does not include other critical factors that affect treatment or prognosis, such as molecular biomarkers.

Reviewer #2:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: The title was attractive and appropriate The method was well written.

→ We thank the reviewer for the encouraging comments. No further comments to add on this.

(1) Science editor:

The study analyzed patients with MRGC, and proposed a prognostic model to classify patient's treatment and outcomes. This model might provide some information for guiding treatment of gastric cancer. However, limitation regarding this study should also be discussed. Meanwhile, therapeutic options for patient beyond this criteria that not valid for this doublet chemotherapy should also be well discussed.

Language Quality: Grade B (Minor language polishing)

Scientific Quality: Grade B (Very good)

→ We thank science editor's for the valuable comments. We added limitations of our study as your recommendation as follow:

Our study also has several limitations. First, despite a large number of patients, the generalizability of this study is limited by its single-center, retrospective design and the single ethnicity of its population. Second, our new prognostic model does not apply to patients who received treatment other than doublet chemotherapy, such as single, triplet, or doublet with trastuzumab. Third, this study does not include other critical factors that affect treatment or prognosis, such as molecular biomarkers.

(2) Company editor-in-chief:

I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Gastroenterology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before its final acceptance, please upload the primary version (PDF) of the Institutional Review Board's official approval in official language of the authors' country to the system; for example, authors from China should upload

the Chinese version of the document, authors from Italy should upload the Italian version of the document, authors from Germany should upload the Deutsch version of the document, and authors from the United States and the United Kingdom should upload the English version of the document, etc.

→ We thank company editor-in-chief's for the comments. We attached the Korean version of the Institutional Review Board's official approval (AMC IRB 2020-0574).